Sugammadex and Smoker's Neuromuscular Block

Study Overview
=================
Brief Summary
-----------------
We compared the durations of antagonizing and of the severity of effect of sugammadex used in antagonizing the rocuronium in smoker and non-smoker total 40 patients with using Train of Four(TOF) neuromuscular monitorization.

Detailed Description
-----------------
40 patients from American Society of Anesthesiologist (ASA) I- II class, being smokers for at least 10 years or non-smokers, who will undergo elective surgery were included in this randomized prospective study. Patients underwent routine monitoring and neuromuscular monitoring. Propofol 2 mg/kg and intravenous fentanyl 1 mcg/kg were applied at induction. After the loss of eyelash reflex, intravenous rocuronium 0,6 mg/kg was administered. The patient was intubated at a Train of Four count of 2. Anesthesia was continued with 50% O2 + 50% air and sevoflurane 2 % . Rocuronium 0,15 mg/kg was administered when TOF (Train of Four) counter reached 2 during the operation. Sugammadex 2 mg/kg was administered at the end of the operation. The time to reach Train of Four values of 0,7-0,8-0,9 were recorded.

Official Title
-----------------
The Evaluation of the Effects of the Use of Rocuronium and Sugammadex on Neuromuscular Block in Smoker

Conditions
-----------------
Neuromuscular Blockade, Smoking

Intervention / Treatment
-----------------
* Drug: sugammadex


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Elective surgery, 1-2 according to the ASA ( American Society of Anesthesiologist ) physical status classification. Patients who have smoked at least 10 packs or have been smoking for 10 years and currently smoking Or never smoked patients Exclusion Criteria: neuromuscular diseases radiotherapy and/or chemotherapy anamnesis, liver and/or renal disease, electrolyte balance, history of drug use which affects neuromuscular transmission, Body Mass Index (BMI) of more than 27, use alcohol

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Smokers<br>The patients who have smoked at least 10 packs or have been smoking for 10 years and currently smoking were included in the smoker group At the end of operation for reversal of neuromuscular blockade sugammadex used. | Drug: sugammadex<br>* At the end of the operation, at least 15 minutes after the last dose of rocuronium, sugammadex 2 mg / kg was administered both of groups<br>* Other names: bridion;|
| Sham Comparator: Nonsmokers<br>The patients who never smoked were included in the non-smoker group At the end of operation for reversal of neuromuscular blockade sugammadex used. | Drug: sugammadex<br>* At the end of the operation, at least 15 minutes after the last dose of rocuronium, sugammadex 2 mg / kg was administered both of groups<br>* Other names: bridion;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Neuromuscular block recovery time | Time to reach TOF %90 measurement after given neuromuscular blocker reverse agent | six months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sugammadex, smoking, neuromuscular blockade